Daxor Corporation

Daxor Corporation company information, Employees & Contact Information

Daxor Corporation (NASDAQ: DXR) is the global leader in blood volume measurement focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 60,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor's vision is optimal blood volume for all. For more information please visit our website at Daxor.com.

Company Details

Employees
53
Founded
-
Address
107 Meco Ln, Oak Ridge,tennessee 37830,united States
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Keywords
New York.
HQ
Oak Ridge, Tennessee
Looking for a particular Daxor Corporation employee's phone or email?

Daxor Corporation Questions

News

Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit - GlobeNewswire

Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit GlobeNewswire

Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System - Yahoo Finance

Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System Yahoo Finance

Daxor Corporation Announces FDA Clearance for Revolutionary Blood Volume Analyzer to Improve Patient Outcomes - Quiver Quantitative

Daxor Corporation Announces FDA Clearance for Revolutionary Blood Volume Analyzer to Improve Patient Outcomes Quiver Quantitative

Breakthrough: FDA Approves Game-Changing Blood Volume Analyzer That Cuts Mortality by 86% - Stock Titan

Breakthrough: FDA Approves Game-Changing Blood Volume Analyzer That Cuts Mortality by 86% Stock Titan

Daxor’s New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25 - GlobeNewswire

Daxor’s New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25 GlobeNewswire

Daxor Corporation Reports Significant Growth and Strategic Developments in Blood Volume Measurement Technology - Nasdaq

Daxor Corporation Reports Significant Growth and Strategic Developments in Blood Volume Measurement Technology Nasdaq

Study Demonstrates Importance and Clinical Utility of Daxor’s Blood Volume (BVA-100) Diagnostic in the Assessment of Heart Failure - Diagnostic and Interventional Cardiology

Study Demonstrates Importance and Clinical Utility of Daxor’s Blood Volume (BVA-100) Diagnostic in the Assessment of Heart Failure Diagnostic and Interventional Cardiology

Next‑Gen BVA System: Daxor Debuts Blood‑Volume Diagnostic at MedAxiom CV Transforum Oct 16–18 - Stock Titan

Next‑Gen BVA System: Daxor Debuts Blood‑Volume Diagnostic at MedAxiom CV Transforum Oct 16–18 Stock Titan

Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter - GlobeNewswire

Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter GlobeNewswire

Blood Volume Measurement Supports Heart Failure Patients, Studies Show - Diagnostic and Interventional Cardiology

Blood Volume Measurement Supports Heart Failure Patients, Studies Show Diagnostic and Interventional Cardiology

Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting - Yahoo Finance

Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting Yahoo Finance

Daxor (NASDAQ: DXR) CEO schedules investor meetings at Maxim Growth Summit, Oct 22–23 - Stock Titan

Daxor (NASDAQ: DXR) CEO schedules investor meetings at Maxim Growth Summit, Oct 22–23 Stock Titan

Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care - GlobeNewswire

Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care GlobeNewswire

Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology’s 74th Annual Scientific Session and Expo - GlobeNewswire

Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology’s 74th Annual Scientific Session and Expo GlobeNewswire

Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA - Yahoo Finance

Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA Yahoo Finance

Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics - Yahoo Finance

Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics Yahoo Finance

Daxor Corporation Announces Pricing of $2.0 million Underwritten Public Offering - GlobeNewswire

Daxor Corporation Announces Pricing of $2.0 million Underwritten Public Offering GlobeNewswire

Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2023 Critical Care Congress - GlobeNewswire

Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2023 Critical Care Congress GlobeNewswire

Daxor Corporation Joins the Heart Failure Society of America (HFSA) as a Corporate Member - GlobeNewswire

Daxor Corporation Joins the Heart Failure Society of America (HFSA) as a Corporate Member GlobeNewswire

Daxor Corporation Closes Q4 2023 with Growth in New Sales to Hospital Systems and Increased Utilization of its BVA-100® Blood Volume Diagnostic Across the U.S. at Existing Accounts - Stock Titan

Daxor Corporation Closes Q4 2023 with Growth in New Sales to Hospital Systems and Increased Utilization of its BVA-100® Blood Volume Diagnostic Across the U.S. at Existing Accounts Stock Titan

Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024 - Stock Titan

Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024 Stock Titan

DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24 - Stock Titan

DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24 Stock Titan

Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network - Stock Titan

Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated Network Stock Titan

Do you know your true blood volume status? - WFLA

Do you know your true blood volume status? WFLA

Daxor Corporation to Exhibit at the Society for Critical Care Medicine 49th Congress - GlobeNewswire

Daxor Corporation to Exhibit at the Society for Critical Care Medicine 49th Congress GlobeNewswire

Daxor Corp. Collaborating With CHF Solutions on Heart Failure Fluid Overload Management - Diagnostic and Interventional Cardiology

Daxor Corp. Collaborating With CHF Solutions on Heart Failure Fluid Overload Management Diagnostic and Interventional Cardiology

Daxor Corporation Selected for U.S. Army Contract to - GlobeNewswire

Daxor Corporation Selected for U.S. Army Contract to GlobeNewswire

Top Daxor Corporation Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant